Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 97,812 | reported | 14 Oct 2020 | tx 126+420,552−456,256 |
| Organon & Co. | 63,054.15 | reported | 13 Jun 2025 | tx 5+58,329.93 |
| Nuvation Bio Inc. | 35,000 | reported | 10 Feb 2021 | tx 3+35,000−25,000 |
| PRECISION BIOSCIENCES INC | 32,800 | reported | 10 May 2021 | tx 2+73,838 |
| BeOne Medicines Ltd. | 19,136 | reported | 21 May 2025 | tx 4+59,124 |
| SUTRO BIOPHARMA, INC. | 18,500 | reported | 06 Jun 2022 | tx 5+86,643 |
| Septerna, Inc. | 16,623 | reported | 17 Jun 2025 | tx 1+16,623 |
| AGENUS INC | 10,000 | reported | 21 Jun 2018 | tx 80+1,968,114−201,424 |
| NEUROCRINE BIOSCIENCES INC | 2,567 | reported | 27 May 2026 | tx 17+57,089−6,300 |
| ARRAY BIOPHARMA INC | 0 | reported | 30 Jul 2019 | tx 11+65,000−90,000 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 27 May 2026 | GRANT_AWARD | NEUROCRINE BIOSCIENCES INC | 2,567 | 0.00 USD | deriv |
| 21 May 2026 | EXERCISE | NEUROCRINE BIOSCIENCES INC | 1,659 | 0.00 USD | |
| 21 May 2026 | EXERCISE | NEUROCRINE BIOSCIENCES INC | 1,659 | 0.00 USD | deriv |
| 17 Jun 2025 | GRANT_AWARD | Septerna, Inc. | 16,623 | 0.00 USD | deriv |
| 13 Jun 2025 | GRANT_AWARD | Organon & Co. | 23,904.38 | 10.04 USD | deriv |
| 21 May 2025 | GRANT_AWARD | BeOne Medicines Ltd. | 10,985 | 0.00 USD | |
| 21 May 2025 | GRANT_AWARD | BeOne Medicines Ltd. | 22,750 | 0.00 USD | deriv |
| 22 May 2025 | EXERCISE | NEUROCRINE BIOSCIENCES INC | 1,435 | 0.00 USD | |
| 21 May 2025 | GRANT_AWARD | NEUROCRINE BIOSCIENCES INC | 3,305 | 0.00 USD | deriv |
| 22 May 2025 | EXERCISE | NEUROCRINE BIOSCIENCES INC | 1,435 | 0.00 USD | deriv |
| 21 May 2025 | GRANT_AWARD | NEUROCRINE BIOSCIENCES INC | 1,659 | 0.00 USD | deriv |
| 30 Sept 2024 | GRANT_AWARD | BeOne Medicines Ltd. | 8,151 | 0.00 USD | |
| 30 Sept 2024 | GRANT_AWARD | BeOne Medicines Ltd. | 17,238 | 0.00 USD | deriv |
| 07 Jun 2024 | GRANT_AWARD | Organon & Co. | 9,638.55 | 20.75 USD | deriv |
| 22 May 2024 | GRANT_AWARD | NEUROCRINE BIOSCIENCES INC | 1,435 | 0.00 USD | deriv |
| 22 May 2024 | GRANT_AWARD | NEUROCRINE BIOSCIENCES INC | 2,982 | 0.00 USD | deriv |
| 17 May 2024 | SALE | NEUROCRINE BIOSCIENCES INC | 1,106 | 141.90 USD | |
| 17 May 2024 | EXERCISE | NEUROCRINE BIOSCIENCES INC | 2,100 | 0.00 USD | |
| 17 May 2024 | EXERCISE | NEUROCRINE BIOSCIENCES INC | 2,100 | 0.00 USD | deriv |
| 23 Jan 2024 | OTHER | Mirati Therapeutics, Inc. | 6,808 | — | |
| 23 Jan 2024 | OTHER | Mirati Therapeutics, Inc. | 5,252 | — | |
| 23 Jan 2024 | OTHER | Mirati Therapeutics, Inc. | 4,162 | — | |
| 23 Jan 2024 | OTHER | Mirati Therapeutics, Inc. | 7,520 | — | deriv |
| 29 Dec 2023 | GRANT_AWARD | Mirati Therapeutics, Inc. | 6,808 | 58.75 USD | |
| 09 Jun 2023 | GRANT_AWARD | Organon & Co. | 10,086 | 19.83 USD | deriv |
1 purchase reported after at least 12 months of silence — most recent on 30 Jan 2014.